Actively Recruiting
Early-Phase Study of IMV102 Injection for Adults Aged 18 to 80 With Relapsed or Refractory Multiple Myeloma
Led by Suzhou Immunofoco Biotechnology Co., Ltd · Updated on 2026-03-30
30
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating IMV102 injection in patients with relapsed or refractory multiple myeloma who have undergone at least three prior therapies. This early-phase clinical study aims to assess the safety and effectiveness of IMV102. The investigation includes dose escalation and expansion phases and is conducted at a single center to better understand how this treatment may affect patients with this condition. Eligible participants will receive an infusion of IMV102 injection. Blood and urine samples will be collected before and after the infusion to analyze how the body processes the drug and to check for immune responses and safety. Tumor responses will be assessed using established criteria at several time points, including baseline, Day 28 after infusion, Month 2, Month 3, and then every three months up to 24 months. Participants will be followed for up to 24 months or until disease progression, new therapy initiation, death, or withdrawal from the study. During this time, researchers will monitor safety, drug levels in the body, immune effects, and treatment efficacy. Assessments include clinical evaluations, laboratory tests, and imaging as needed. This close monitoring helps to understand the treatments impact and safety profile over time.
CONDITIONS
Brief Title
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Research Team
J
Juan Du, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
